Hepatocellular carcinoma specific graded prognostic assessment can predict outcomes for patients with brain metastases from hepatocellular carcinoma

Seungtaek Lim, Soohyeon Lee, Jae Yun Lim, Ji Soo Park, Jinsil Seong, Won Seok Chang, KwangHyub Han, Hye Jin Choi

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Stratifying patients with brain metastasis (BM) from hepatocellular carcinoma (HCC) by prognostic factors can be useful when making treatment decisions. Nevertheless, a diagnosis-specific graded prognostic assessment (GPA) for HCC has not been well established. We retrospectively reviewed the data from 118 HCC patients newly diagnosed with BM at the Yonsei University Health System between 1985 and 2011. After univariate and multivariate analyses of prognostic factors, those shown to significantly affect survival were used to develop a HCC-specific GPA (HCC-GPA) index. The median overall survival after BM in all patients was 6.1 weeks (95 % confidence interval 4.8–7.4 weeks). Using the prognostic factors identified via multivariate analysis, we developed a HCC-GPA index, including number of brain metastases (single: 0.5, multiple: 0 points), alpha-feto protein (<400 ng/mL: 0.5, ≥400 ng/mL: 0 points), and Child-Pugh-Score (A: 3, B: 2, C: 0 points). There were no survival differences for age, sex, performance status, and time interval from initial diagnosis to development of BM. Median survival times from BM were discriminable when applying the HCC-GPA scoring system: 1.7, 3.2, 7.9, and 27.0 weeks for HCC-GPA scores of 0–1.0 (N = 16), 1.5–2.5 (N = 32), 3.0–3.5 (N = 49), and 4.0 (N = 21), respectively (P < 0.001). Although the prognoses of patients with BM from HCC are dismal, the newly developed HCC-GPA index can be used to discriminate the expected prognoses thereof. Moreover, the index may hold value as a tool for selecting patients who may be good candidates for active local treatment.

Original languageEnglish
Pages (from-to)199-207
Number of pages9
JournalJournal of Neuro-Oncology
Volume120
Issue number1
DOIs
Publication statusPublished - 2014 Sep 27

Fingerprint

Hepatocellular Carcinoma
Neoplasm Metastasis
Brain
Survival
Multivariate Analysis
Sex Characteristics
Decision Making
Confidence Intervals
Health
Therapeutics
Proteins

All Science Journal Classification (ASJC) codes

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

Lim, Seungtaek ; Lee, Soohyeon ; Lim, Jae Yun ; Park, Ji Soo ; Seong, Jinsil ; Chang, Won Seok ; Han, KwangHyub ; Choi, Hye Jin. / Hepatocellular carcinoma specific graded prognostic assessment can predict outcomes for patients with brain metastases from hepatocellular carcinoma. In: Journal of Neuro-Oncology. 2014 ; Vol. 120, No. 1. pp. 199-207.
@article{b82360d615b84577a582a316e833faa5,
title = "Hepatocellular carcinoma specific graded prognostic assessment can predict outcomes for patients with brain metastases from hepatocellular carcinoma",
abstract = "Stratifying patients with brain metastasis (BM) from hepatocellular carcinoma (HCC) by prognostic factors can be useful when making treatment decisions. Nevertheless, a diagnosis-specific graded prognostic assessment (GPA) for HCC has not been well established. We retrospectively reviewed the data from 118 HCC patients newly diagnosed with BM at the Yonsei University Health System between 1985 and 2011. After univariate and multivariate analyses of prognostic factors, those shown to significantly affect survival were used to develop a HCC-specific GPA (HCC-GPA) index. The median overall survival after BM in all patients was 6.1 weeks (95 {\%} confidence interval 4.8–7.4 weeks). Using the prognostic factors identified via multivariate analysis, we developed a HCC-GPA index, including number of brain metastases (single: 0.5, multiple: 0 points), alpha-feto protein (<400 ng/mL: 0.5, ≥400 ng/mL: 0 points), and Child-Pugh-Score (A: 3, B: 2, C: 0 points). There were no survival differences for age, sex, performance status, and time interval from initial diagnosis to development of BM. Median survival times from BM were discriminable when applying the HCC-GPA scoring system: 1.7, 3.2, 7.9, and 27.0 weeks for HCC-GPA scores of 0–1.0 (N = 16), 1.5–2.5 (N = 32), 3.0–3.5 (N = 49), and 4.0 (N = 21), respectively (P < 0.001). Although the prognoses of patients with BM from HCC are dismal, the newly developed HCC-GPA index can be used to discriminate the expected prognoses thereof. Moreover, the index may hold value as a tool for selecting patients who may be good candidates for active local treatment.",
author = "Seungtaek Lim and Soohyeon Lee and Lim, {Jae Yun} and Park, {Ji Soo} and Jinsil Seong and Chang, {Won Seok} and KwangHyub Han and Choi, {Hye Jin}",
year = "2014",
month = "9",
day = "27",
doi = "10.1007/s11060-014-1546-7",
language = "English",
volume = "120",
pages = "199--207",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "1",

}

Hepatocellular carcinoma specific graded prognostic assessment can predict outcomes for patients with brain metastases from hepatocellular carcinoma. / Lim, Seungtaek; Lee, Soohyeon; Lim, Jae Yun; Park, Ji Soo; Seong, Jinsil; Chang, Won Seok; Han, KwangHyub; Choi, Hye Jin.

In: Journal of Neuro-Oncology, Vol. 120, No. 1, 27.09.2014, p. 199-207.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Hepatocellular carcinoma specific graded prognostic assessment can predict outcomes for patients with brain metastases from hepatocellular carcinoma

AU - Lim, Seungtaek

AU - Lee, Soohyeon

AU - Lim, Jae Yun

AU - Park, Ji Soo

AU - Seong, Jinsil

AU - Chang, Won Seok

AU - Han, KwangHyub

AU - Choi, Hye Jin

PY - 2014/9/27

Y1 - 2014/9/27

N2 - Stratifying patients with brain metastasis (BM) from hepatocellular carcinoma (HCC) by prognostic factors can be useful when making treatment decisions. Nevertheless, a diagnosis-specific graded prognostic assessment (GPA) for HCC has not been well established. We retrospectively reviewed the data from 118 HCC patients newly diagnosed with BM at the Yonsei University Health System between 1985 and 2011. After univariate and multivariate analyses of prognostic factors, those shown to significantly affect survival were used to develop a HCC-specific GPA (HCC-GPA) index. The median overall survival after BM in all patients was 6.1 weeks (95 % confidence interval 4.8–7.4 weeks). Using the prognostic factors identified via multivariate analysis, we developed a HCC-GPA index, including number of brain metastases (single: 0.5, multiple: 0 points), alpha-feto protein (<400 ng/mL: 0.5, ≥400 ng/mL: 0 points), and Child-Pugh-Score (A: 3, B: 2, C: 0 points). There were no survival differences for age, sex, performance status, and time interval from initial diagnosis to development of BM. Median survival times from BM were discriminable when applying the HCC-GPA scoring system: 1.7, 3.2, 7.9, and 27.0 weeks for HCC-GPA scores of 0–1.0 (N = 16), 1.5–2.5 (N = 32), 3.0–3.5 (N = 49), and 4.0 (N = 21), respectively (P < 0.001). Although the prognoses of patients with BM from HCC are dismal, the newly developed HCC-GPA index can be used to discriminate the expected prognoses thereof. Moreover, the index may hold value as a tool for selecting patients who may be good candidates for active local treatment.

AB - Stratifying patients with brain metastasis (BM) from hepatocellular carcinoma (HCC) by prognostic factors can be useful when making treatment decisions. Nevertheless, a diagnosis-specific graded prognostic assessment (GPA) for HCC has not been well established. We retrospectively reviewed the data from 118 HCC patients newly diagnosed with BM at the Yonsei University Health System between 1985 and 2011. After univariate and multivariate analyses of prognostic factors, those shown to significantly affect survival were used to develop a HCC-specific GPA (HCC-GPA) index. The median overall survival after BM in all patients was 6.1 weeks (95 % confidence interval 4.8–7.4 weeks). Using the prognostic factors identified via multivariate analysis, we developed a HCC-GPA index, including number of brain metastases (single: 0.5, multiple: 0 points), alpha-feto protein (<400 ng/mL: 0.5, ≥400 ng/mL: 0 points), and Child-Pugh-Score (A: 3, B: 2, C: 0 points). There were no survival differences for age, sex, performance status, and time interval from initial diagnosis to development of BM. Median survival times from BM were discriminable when applying the HCC-GPA scoring system: 1.7, 3.2, 7.9, and 27.0 weeks for HCC-GPA scores of 0–1.0 (N = 16), 1.5–2.5 (N = 32), 3.0–3.5 (N = 49), and 4.0 (N = 21), respectively (P < 0.001). Although the prognoses of patients with BM from HCC are dismal, the newly developed HCC-GPA index can be used to discriminate the expected prognoses thereof. Moreover, the index may hold value as a tool for selecting patients who may be good candidates for active local treatment.

UR - http://www.scopus.com/inward/record.url?scp=84910153617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84910153617&partnerID=8YFLogxK

U2 - 10.1007/s11060-014-1546-7

DO - 10.1007/s11060-014-1546-7

M3 - Article

C2 - 25062667

AN - SCOPUS:84910153617

VL - 120

SP - 199

EP - 207

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1

ER -